Lv1
30 积分 2024-08-07 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2天前
已完结
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
23天前
已完结
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
1个月前
已完结
Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro
3个月前
已完结
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models
3个月前
已完结
Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies
3个月前
已完结
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma
3个月前
已完结
Current landscape of CD3 bispecific antibodies in hematologic malignancies
3个月前
已完结
皖公网安备34019202002308
